Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repros Therapeutics has started patient dosing in the final cohort of a Phase 2 low-dose trial evaluating oral Proellex.
Subscribe to our email newsletter
The trial aims to assess the impact of the drug on menstrual events, as well as liver function.
In the trial, the patients will be administered with 12mg of Proellex per day.
In earlier study, Proellex demonstrated improvement as compared to placebo in all three elements of pain typically associated with the disorder; dysmenorrhea (menstrual pain), non menstrual pelvic pain, and dyspareunia (pain during sex).